CSL downgrades annual guidance and signals $5 billion in new impairments
Updated
Updated · MarketWatch · May 10
CSL downgrades annual guidance and signals $5 billion in new impairments
8 articles · Updated · MarketWatch · May 10
The drugmaker now expects about $15.2 billion in revenue and $3.1 billion underlying net profit for the year to June, with Vifor among assets facing pretax write-downs.
CSL said slower-than-expected gains from growth initiatives, a $300 million US inventory effect, a $200 million China hit and other pressures including Middle East conflict hurt outlook.
It still expects second-half sales growth at CSL Behring and a somewhat stronger Seqirus performance, while the new impairments will be booked across fiscal 2026 and 2027.
CSL is writing down $5 billion. Is its restructuring plan enough to fend off new competition and reverse its decline?
CSL's profit warning is tied to its Vifor deal. Was this acquisition a disastrous misstep for the biotech giant?
Is CSL's profit warning a sign the plasma industry faces an existential threat from newer biotech innovations?